Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25554375 | 1.00 | HDAC8 (0.60) | HDAC8KMOUTS2RERN1GRM5 | |
| SCHEMBL31331693 | 0.87 | HDAC8 (0.64) | HDAC8KMOERN1GRM5ALDH1A1 | |
| SCHEMBL1927786 | 0.87 | HDAC8 (0.64) | HDAC8KMOERN1GRM5ALDH1A1 | |
| SCHEMBL4652059 | 0.85 | NPC1 (0.62) | MMEALDH1A1 | |
| SCHEMBL1750579 | 0.85 | NPC1 (0.62) | MMEALDH1A1 | |
| SCHEMBL6519640 | 0.85 | NPC1 (0.62) | MMEALDH1A1 | |
| SCHEMBL2796740 | 0.84 | CA1 (0.62) | HDAC8ALDH1A1 | |
| SCHEMBL698880 | 0.84 | CA1 (0.62) | HDAC8ALDH1A1 | |
| SCHEMBL698879 | 0.84 | CA1 (0.62) | HDAC8ALDH1A1 | |
| SCHEMBL31432652 | 0.81 | HDAC8 (0.57) | HDAC8UTS2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | HDAC8 1744/4885KMO 2095/4885UTS2R 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.